Latest Breaking News On - Ad cooperative study - Page 1 : vimarsana.com

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

EISAI TO PRESENT DATA ON LECANEMAB and OTHER ALZHEIMER'S DISEASE RESEARCH AT THE AD/PD™ 2024 ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™) from March 5-9 in Lisbon, Portugal, and virtually. The lecanemab data and additional research findings from Eis

Biogen : "LEQEMBI® Intravenous Infusion" (Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20 -December 12, 2023 at 09:19 pm EST

TOKYO and CAMBRIDGE, Mass., December 12, 2023 - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta monoclonal antibody LEQEMBI®.

BioVie to announce topline data from Phase 3 Alzheimer's Disease trial by year-end

BioVie Inc (NASDAQ:BIVI) said the last patient has completed their final visit at week 30 in their Phase 3 study of investigational therapy NE3107 in.

Eisai Co., Ltd. - LEQEMBI Intravenous Infusion Approved for the Treatment of Alzheimer's disease in Japan

TOKYO - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta monoclonal antibody LEQEMBI Intravenous Infusion has been approved in Japan as a.